Dr. John M. Floberg
Claim this profileUniversity of Wisconsin Carbone Cancer Center
Studies Prostate Cancer
Studies Prostate Adenocarcinoma
4 reported clinical trials
16 drugs studied
Affiliated Hospitals
Clinical Trials John M. Floberg is currently running
Radioactive Drug Therapy
for Prostate Cancer
This trial studies how well lutetium Lu 177 dotatate works in treating patients with a specific type of prostate cancer that has spread. The drug targets cancer cells and releases radiation to kill them. Lutetium-177 (Lu-177) PSMA therapy is a targeted treatment for advanced prostate cancer that has shown promising results.
Recruiting1 award Phase 216 criteria
Apalutamide + Targeted Radiation
for Prostate Cancer
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting2 awards Phase 3
More about John M. Floberg
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments John M. Floberg has experience with
- Bicalutamide
- Degarelix
- Histrelin
- Leuprolide
- Relugolix
- Buserelin
Breakdown of trials John M. Floberg has run
Prostate Cancer
Prostate Adenocarcinoma
Cancer
Adenocarcinoma
Neuroendocrine Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John M. Floberg specialize in?
John M. Floberg focuses on Prostate Cancer and Prostate Adenocarcinoma. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is John M. Floberg currently recruiting for clinical trials?
Yes, John M. Floberg is currently recruiting for 3 clinical trials in Madison Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that John M. Floberg has studied deeply?
Yes, John M. Floberg has studied treatments such as Bicalutamide, Degarelix, Histrelin.
What is the best way to schedule an appointment with John M. Floberg?
Apply for one of the trials that John M. Floberg is conducting.
What is the office address of John M. Floberg?
The office of John M. Floberg is located at: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin 53792 United States. This is the address for their practice at the University of Wisconsin Carbone Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.